@article{3a4c0c5a190142fdbddc9890ddb8f471,
title = "Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: A GioTag study US patient analysis",
abstract = "Aim: To assess time-to-treatment failure (TTF) in US patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib-osimertinib treatment in the global, observational GioTag study. Patients & methods: Patients had EGFR T790M mutation-positive disease after first-line afatinib and subsequently received osimertinib. The primary outcome was TTF. Results: In 129 patients at US centers, median TTF was 28.4 months (90% CI: 27.0-34.1). Median overall survival was 47.6 months (90% CI: 35.5-51.5). Conclusion: Sequential afatinib-osimertinib in this US-treated population was associated with long median TTF and represents an effective, evidence-based treatment option for US patients with EGFR mutation-positive NSCLC not presenting with active brain metastases or de novo T790M. Clinical Trial Registration: NCT03370770 (ClinicalTrials.gov.",
keywords = "NSCLC, afatinib, osimertinib, sequential treatment",
author = "Bruce Feinberg and Balazs Halmos and Rasim Gucalp and Wenbo Tang and Barbara Moehring and Hochmair, {Maximillian J.}",
note = "Funding Information: The authors are grateful to the patients, their families, the investigators and staff who participated in the study. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors received no direct compensation related to the development of the manuscript. Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations. There is no applicable grant number. Funding Information: The study was supported by Boehringer Ingelheim. B Feinberg is an employee of Cardinal Health. B Halmos reports grant/research support from Boehringer Ingelheim, Merck Sharp & Dohme, AstraZeneca, Novartis, Pfizer, Bristol-Myers Squibb, Mirati, Takeda, AbbVie, Eli-Lilly and Guardant Health and consultancy roles for Boehringer Ingelheim, AstraZeneca, Genentech, Novartis, Pfizer, Bristol-Myers Squibb, Merck Sharp & Dohme, Spectrum and Guardant Health. R Gucalp reports no potential conflicts. W Tang is an employee of Boehringer Ingelheim. B Moehring is an employee of Boehringer Ingelheim. MJ Hochmair reports consultancy roles for AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Roche and Takeda and participation in speakers{\textquoteright} bureaus for AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer and Roche. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2020 ",
year = "2020",
month = aug,
doi = "10.2217/fon-2020-0188",
language = "English (US)",
volume = "16",
pages = "1585--1595",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "22",
}
